Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. 1995

E P Winer, and L Chu, and D V Spicer
Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA.

Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) has been formulated as a liquid-filled, soft gelatin capsule. Pharmacokinetic studies of this agent indicate that it has a large volume of distribution, a long terminal half-life, and a high clearance rate. The pharmacokinetics of vinorelbine are similar whether the drug is administered orally or intravenously. Oral vinorelbine has a low bioavailability, which may be due to a high first-pass effect. Preliminary results from two multicenter phase II trials of oral vinorelbine in patients with advanced breast cancer are presented. In one study of 98 advanced breast cancer patients aged 65 years and older with limited prior therapy, the response rate of oral vinorelbine was 24% (complete response, 5%; partial response, 19%). In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%). In both studies, oral vinorelbine was generally well tolerated. As with intravenous administration, neutropenia is common and neuropathy is infrequent. In contrast to intravenous administration, nausea, vomiting, and diarrhea are common. Based on these preliminary results, further clinical investigation of oral vinorelbine is warranted.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077235 Vinorelbine A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. 5'-Nor-anhydrovinblastine,KW 2307,KW-2307,Navelbine,Vinorelbine Tartrate,5' Nor anhydrovinblastine,KW2307
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014747 Vinblastine Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Vincaleukoblastine,Cellblastin,Lemblastine,Velban,Velbe,Vinblastin Hexal,Vinblastina Lilly,Vinblastine Sulfate,Vinblastinsulfat-Gry,Sulfate, Vinblastine
D017322 Clinical Trials, Phase II as Topic Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries. Drug Evaluation, FDA Phase 2 as Topic,Drug Evaluation, FDA Phase II as Topic,Evaluation Studies, FDA Phase 2 as Topic,Evaluation Studies, FDA Phase II as Topic

Related Publications

E P Winer, and L Chu, and D V Spicer
May 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
E P Winer, and L Chu, and D V Spicer
April 1995, Seminars in oncology,
E P Winer, and L Chu, and D V Spicer
April 1995, Seminars in oncology,
E P Winer, and L Chu, and D V Spicer
April 1995, Seminars in oncology,
E P Winer, and L Chu, and D V Spicer
October 1994, Seminars in oncology,
E P Winer, and L Chu, and D V Spicer
April 2000, Gastroenterologie clinique et biologique,
E P Winer, and L Chu, and D V Spicer
July 1999, Oncology (Williston Park, N.Y.),
E P Winer, and L Chu, and D V Spicer
April 1989, Seminars in oncology,
E P Winer, and L Chu, and D V Spicer
February 2001, Oncology (Williston Park, N.Y.),
E P Winer, and L Chu, and D V Spicer
October 1994, Seminars in oncology,
Copied contents to your clipboard!